Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The company's lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney injuries in patients undergoing open heart surgery. The company also has preclinical candidate drugs intended for the treatment of chronic kidney disease, targeting specific disease segments such as FSGS, IgAN, Alport Syndrome and DKD. Listed on Nasdaq First North Growth Market.
| Website | http://guardtherapeutics.com |
| Employees | 10 (6 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
Nginx
+4 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Kidney Disease Treatment, Kidney Health, Kidney Failure Treatment, Chronic Kidney Disease, Therapeutic Drug Development, Clinical Stage Biopharmaceutical |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck AH, Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences +39 more (view full list) |
Looking for a particular Guard Therapeutics employee's phone or email?
Tobias Agervald is the CEO of Guard Therapeutics.
6 people are employed at Guard Therapeutics.